IHC 2021 | Treatment targets for headache: delta and kappa opioid receptors
Amynah Pradhan
• 7 Sep 2021
Amynah Pradhan, PhD, University of Illinois at Chicago, Chicago, IL, discusses the use of delta and kappa opioid receptors as headache treatment targets. Dr Pradhan talks on the current research that has been done into delta opioid receptors, suggesting that its activation has antimigraine effects. Research into kappa opioid receptors suggests their inhibition or antagonist activation may be a way to reduce migraines, especially those which are stress-induced. This interview took place during the International Headache Congress 2021.
